Pharma Mar, S.A.
PHMMF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $42 | $56 | $39 | $48 |
| % Growth | -25.8% | 45.1% | -19.7% | – |
| Cost of Goods Sold | $5 | $3 | $3 | $1 |
| Gross Profit | $37 | $54 | $35 | $47 |
| % Margin | 87.9% | 95.1% | 91.2% | 97.3% |
| R&D Expenses | $26 | $26 | $21 | $28 |
| G&A Expenses | $0 | $7 | $8 | -$20 |
| SG&A Expenses | $14 | $15 | $14 | -$37 |
| Sales & Mktg Exp. | $0 | $7 | $6 | -$16 |
| Other Operating Expenses | $4 | -$11 | $4 | $51 |
| Operating Expenses | $44 | $29 | $39 | $42 |
| Operating Income | -$7 | $24 | -$3 | $5 |
| % Margin | -17.3% | 42.8% | -7.9% | 10.1% |
| Other Income/Exp. Net | $2 | -$1 | -$1 | $5 |
| Pre-Tax Income | -$5 | $23 | -$4 | $10 |
| Tax Expense | $0 | -$0 | $0 | -$9 |
| Net Income | -$5 | $23 | -$4 | $19 |
| % Margin | -11.5% | 41.4% | -10.2% | 38.6% |
| EPS | -0.28 | 1.35 | -0.23 | 1.06 |
| % Growth | -120.7% | 687% | -121.7% | – |
| EPS Diluted | -0.28 | 1.35 | -0.23 | 1.06 |
| Weighted Avg Shares Out | 17 | 17 | 17 | 18 |
| Weighted Avg Shares Out Dil | 17 | 17 | 17 | 18 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $5 |
| Interest Expense | $0 | $1 | $1 | $2 |
| Depreciation & Amortization | $2 | $2 | $2 | $2 |
| EBITDA | -$2 | $26 | -$1 | $15 |
| % Margin | -5.5% | 46.4% | -2.8% | 31.4% |